Electronic Structure of Above-Room-Temperature van der Waals Ferromagnet Fe₃GaTe₂

Fe3GaTe2, a recently discovered van der Waals ferromagnet, demonstrates intrinsic ferromagnetism above room temperature, necessitating a comprehensive investigation of the microscopic origins of its high Curie temperature (TC). In this study, we reveal the electronic structure of Fe3GaTe2 in its ferromagnetic ground state using angle-resolved photoemission spectroscopy and density functional theory calculations. Our results establish a consistent correspondence between the measured band structure and theoretical calculations, underscoring the significant contributions of the Heisenberg exchange interaction (Jex) and magnetic anisotropy energy to the development of the high-TC ferromagnetic ordering in Fe3GaTe2. Intriguingly, we observe substantial modifications to these crucial driving factors through doping, which we attribute to alterations in multiple spin-splitting bands near the Fermi level. These findings provide valuable insights into the underlying electronic structure and its correlation with the emergence of high-TC ferromagnetic ordering in Fe3GaTe2

Data_Sheet_1_1_Advanced fructo-oligosaccharides improve itching and aberrant epidermal lipid composition in children with atopic dermatitis.xlsx

IntroductionThe effects of fructo-oligosaccharides (FOS) on atopic dermatitis (AD) have not been determined.MethodsIn a randomized, double-blind, placebo-controlled trial, children with AD aged 24 months to 17 years received either advanced FOS containing 4.25 g of 1-kestose or a placebo (maltose) for 12 weeks.ResultsThe SCORAD and itching scores were reduced in patients treated with both FOS (all p DiscussionFOS may be beneficial in alleviating itching and sleep disturbance, as well as improving skin barrier function in children with AD.</p

Image_1_Advanced fructo-oligosaccharides improve itching and aberrant epidermal lipid composition in children with atopic dermatitis.JPEG

IntroductionThe effects of fructo-oligosaccharides (FOS) on atopic dermatitis (AD) have not been determined.MethodsIn a randomized, double-blind, placebo-controlled trial, children with AD aged 24 months to 17 years received either advanced FOS containing 4.25 g of 1-kestose or a placebo (maltose) for 12 weeks.ResultsThe SCORAD and itching scores were reduced in patients treated with both FOS (all p DiscussionFOS may be beneficial in alleviating itching and sleep disturbance, as well as improving skin barrier function in children with AD.</p